51. [Dawn of Cancer Clinical Sequencing in Chiba University Hospital].
- Author
-
Kano M, Miyauchi H, Matsushita K, Murakami K, Toyozumi T, Hayano K, Otsuka R, Takahashi M, Sekino N, Shiraishi T, Arai M, Takiguchi Y, and Matsubara H
- Subjects
- Genome, Human, High-Throughput Nucleotide Sequencing, Hospitals, University, Humans, Japan, Patient Care Team, Neoplasms genetics
- Abstract
Genome medicine has been attractingmuch of attention in Japan. The combination of molecular targetingdrug s and somatic mutations has been developed for cancer treatment, which was introduced clinically with evidence by cancer type. Several cancer somatic mutations can be identified in a single test inexpensively using next-generation sequencing(NGS). Drug approval not based on organs but on cancer genome analysis has been practiced mainly in the United States, and is also being implemented in Japan. However, cancer treatment strategies using molecular targeting drugs and the associated diagnosis are limited in each type of cancer. Furthermore, the benefit of NGS, which is an improved and inexpensive technique, is still insignificant in Japan. However, the clinical biobank system was initiated in 2011 to prepare the era of cancer genome medicine in our department. The quality of biological samples was strictly controlled by the standardized sampling procedures, which can be used by the researchers accordingto their convenience. Furthermore, the cooperative research involvingcommercial corporations has been started.
- Published
- 2018